Bristol-Myers Squibb  Onglyza / Kombiglyze  (known in the EU as  Onglyza / Komboglyze ) — a once-daily oral tablet for the treatment of type 2 diabetes that is  part of our strategic alliance with AstraZeneca  Byetta  — a twice daily glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes  Bydureon  — a once-weekly GLP-1 receptor agonist for the treatment of type 2 diabetes  The estimated U.S. prescription change data provided throughout this report includes information only from the retail and mail order  channels and does not reflect product demand within other channels such as hospitals, home health care, clinics, federal facilities  including Veterans Administration hospitals, and long-term care, among others. The data is provided by Wolters Kluwer Health  (WK), except for  Sprycel , and is based on the Source Prescription Audit. Sprycel  demand is based upon information from the Next- Generation Prescription Service version 2.0 of the National Prescription Audit provided by the IMS Health (IMS). The data is a  product of each respective service providers’ own recordkeeping and projection processes and therefore subject to the inherent  limitations of estimates based on sampling and may include a margin of error.  We continuously seek to improve the quality of our estimates of prescription change amounts and ultimate patient/consumer demand  by reviewing the calculation methodologies employed and analyzing internal and third-party data. We expect to continue to review  and refine our methodologies and processes for calculation of these estimates and will monitor the quality of our own and third  parties’ data used in such calculations.  We calculated the estimated total U.S. prescription change on a weighted-average basis to reflect the fact that mail order prescriptions  include a greater volume of product supplied, compared to retail prescriptions. Mail order prescriptions typically reflect a 90-day  prescription whereas retail prescriptions typically reflect a 30-day prescription. The calculation is derived by multiplying mail order  prescription data by a factor that approximates three and adding to this the retail prescriptions. We believe that a calculation of  estimated total U.S. prescription change based on this weighted-average approach provides a superior estimate of total prescription  demand in retail and mail order channels. We use this methodology for our internal demand reporting.  12 • U.S. net sales of  Onglyza / Kombiglyze  increased in both periods primarily due to higher overall demand and higher average net  selling prices in 2012.  was launched in the U.S. in the fourth quarter of 2010.  • International net sales increased in both periods primarily due to higher demand, which was partially offset by unfavorable  foreign exchange in 2012. • Byetta  net sales are included in our results following the completion of our acquisition of Amylin in the third quarter of 2012.  • Bydureon  was launched by Amylin in the U.S. in the first quarter of 2012 and in the EU in the second quarter of 2012. Net sales  are included in our results following the completion of our acquisition of Amylin in the third quarter of 2012.  • U.S. net sales continued to decrease in 2012 from generic erosion of certain products which was partially offset by sales of  Symlin following the completion of our Amylin acquisition in the third quarter of 2012.  • International net sales decreased in both periods due to the continued generic erosion of certain brands and unfavorable foreign  exchange in 2012.  Mature Products and All Other — includes all other products, including those which have lost exclusivity in major markets, over-the- counter brands and royalty-related revenue 